Literature DB >> 7669577

A possible screening test for inherited p53-related defects based on the apoptotic response of peripheral blood lymphocytes to DNA damage.

R S Camplejohn1, P Perry, S V Hodgson, G Turner, A Williams, C Upton, C MacGeoch, S Mohammed, D M Barnes.   

Abstract

The cellular response, in terms of cell cycle arrest(s) and apoptosis, to radiation-induced DNA damage was studied. Experiments were performed on both mitogen-stimulated and resting peripheral blood lymphocytes (PBLs) from normal and cancer-prone (C-P) individuals. The C-P individuals comprised three patients carrying germline p53 mutations and three members of two families apparently without such mutations, but with an inherited defect which results in p53 deregulation as shown by high levels of stabilised p53 protein in normal tissues. Interestingly, mitogen-stimulated PBL, from both normal and C-P individuals failed to demonstrate a G1 arrest after gamma radiation. However, a clear difference was seen in the apoptotic response to DNA damage, of PBL from normal and C-P individuals; PBLs from C-P individuals with inherited p53-related defects had a reduced apoptotic response (P = 0.0003). There was a wide margin of separation, with no overlap between the two groups, supporting the possibility of using this altered apoptotic response as a screening test. This simple and rapid procedure could be used to identify those individuals in a C-P family who carry germline p53-related defects. The method appears to detect both individuals with p53 mutations and those apparently without mutations but with other p53-related defects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7669577      PMCID: PMC2033866          DOI: 10.1038/bjc.1995.390

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  Thymocyte apoptosis induced by p53-dependent and independent pathways.

Authors:  A R Clarke; C A Purdie; D J Harrison; R G Morris; C C Bird; M L Hooper; A H Wyllie
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

2.  p53 is required for radiation-induced apoptosis in mouse thymocytes.

Authors:  S W Lowe; E M Schmitt; S W Smith; B A Osborne; T Jacks
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

3.  p53-mediated cell death: relationship to cell cycle control.

Authors:  E Yonish-Rouach; D Grunwald; S Wilder; A Kimchi; E May; J J Lawrence; P May; M Oren
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

4.  Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells.

Authors:  J J Ryan; R Danish; C A Gottlieb; M F Clarke
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

5.  Conformation changes of p53 proteins in regulation of murine T lymphocyte proliferation.

Authors:  J Wu; M Wang; X Li; Y Sheng
Journal:  Cell Mol Biol Res       Date:  1993

Review 6.  Predictive testing for germline mutations in the p53 gene: are all the questions answered?

Authors:  R A Eeles
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

Review 7.  The tumor suppressor p53.

Authors:  L A Donehower; A Bradley
Journal:  Biochim Biophys Acta       Date:  1993-08-23

8.  High levels of p53 protein in UV-irradiated normal human skin.

Authors:  P A Hall; P H McKee; H D Menage; R Dover; D P Lane
Journal:  Oncogene       Date:  1993-01       Impact factor: 9.867

9.  Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.

Authors:  J M Birch; A L Hartley; K J Tricker; J Prosser; A Condie; A M Kelsey; M Harris; P H Jones; A Binchy; D Crowther
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

10.  p53 mutations increase resistance to ionizing radiation.

Authors:  J M Lee; A Bernstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

View more
  14 in total

Review 1.  [Significance of apoptotic processes in radiotherapy. II].

Authors:  M Abend; D van Beuningen
Journal:  Strahlenther Onkol       Date:  1998-04       Impact factor: 3.621

Review 2.  P53, apoptosis, and breast cancer.

Authors:  D M Barnes; R S Camplejohn
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-04       Impact factor: 2.673

3.  The need for dynamic methods for measuring cell cycle perturbations: a study in radiation-treated lymphoblastoid cell lines of varying p53 status.

Authors:  R Gilchrist; M E Lomax; R S Camplejohn
Journal:  Cell Prolif       Date:  1999-02       Impact factor: 6.831

4.  Li-fraumeni syndrome.

Authors:  David Malkin
Journal:  Genes Cancer       Date:  2011-04

Review 5.  p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours.

Authors:  R S Camplejohn; J Rutherford
Journal:  Cell Prolif       Date:  2001-02       Impact factor: 6.831

Review 6.  Li-Fraumeni syndrome--a molecular and clinical review.

Authors:  J M Varley; D G Evans; J M Birch
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  Investigations on a clinically and functionally unusual and novel germline p53 mutation.

Authors:  J Rutherford; C E Chu; P M Duddy; R S Charlton; P Chumas; G R Taylor; X Lu; D M Barnes; R S Camplejohn
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

8.  Number of rare germline CNVs and TP53 mutation types.

Authors:  Amanda G Silva; Isabel Maria W Achatz; Ana Cv Krepischi; Peter L Pearson; Carla Rosenberg
Journal:  Orphanet J Rare Dis       Date:  2012-12-21       Impact factor: 4.123

9.  No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines.

Authors:  K J Williams; J Heighway; J M Birch; J D Norton; D Scott
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

10.  Is telomere length in peripheral blood lymphocytes correlated with cancer susceptibility or radiosensitivity?

Authors:  J Barwell; L Pangon; A Georgiou; Z Docherty; I Kesterton; J Ball; R Camplejohn; J Berg; A Aviv; J Gardner; B S Kato; N Carter; D Paximadas; T D Spector; S Hodgson
Journal:  Br J Cancer       Date:  2007-11-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.